News & Views
Patent Approval for GPCR Biosensors
Feb 26 2020
French biopharma Domain Therapeutics, developers of drug candidates targeting G Protein-Coupled Receptors (GPCR) in neurology, oncology and rare diseases, has been granted a patent in the US and in Europe, covering a novel family of biosensors that monitor biomolecule localisation and trafficking in cells.
The patent, was initially filed by Prof. Michel Bouvier and his team and is part of the technology licensed to Domain Therapeutics by the Universities of Montreal and McGill, Canada. The biosensors are designed to profile G Proteins, including G12 and G13, Beta-arrestins, second messengers and receptor trafficking.
“This granted patent illustrates our strategy to stay at the forefront of innovation in technologies for challenging GPCRs. It will help the company address unmet medical needs with drugs acting through brand new mechanisms of action,” said Pascal Neuville, CEO, Domain Therapeutics. “In collaboration with Prof. Michel Bouvier, we have already taken advantage of this unique technology to launch a chaperone program targeting a mutated GPCR with impaired trafficking.”
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China